MedTrace Logo

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

NCT03331250 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-12-23

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).

-The drug involved in this study is Eribulin

Conditions

  • Angiosarcoma
  • Epithelioid Hemangioendothelioma

Interventions

DRUG

Eribulin

It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Gregory Cote, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2023-07-21
Completion
2026-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03331250 on ClinicalTrials.gov